Valuation dashboard for Lifecore Biomedical, Inc. (LFCR) with P/E N/A, P/B 9.74, EV/EBITDA -73.17 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities.
Analysis Summary
Lifecore Biomedical, Inc. reported revenue of $129.5M in the most recent fiscal year, growing at a 5-year CAGR of 5.1%.
Trailing-twelve-month margins: gross margin 29.7%, operating margin -2.1%, net margin -30.4%.
At the current price of $4.16, LFCR has negative trailing earnings (P/E not meaningful) and an ROE of -376.95%. Market capitalisation stands at $156M.
Balance sheet quality for LFCR: current ratio of 3.5. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 9.74 |
| EV / EBITDA | -73.17 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| LFCR | Lifecore Biomedical, Inc. | $156M | 9.74 | -376.9% | |
| TAK | Takeda Pharmaceutical Company Limited | $59.4B | 51.19 | 1.21 | 2.6% |
| TEVA | Teva Pharmaceutical Industries Limited | $45.0B | 61.47 | 5.82 | 17.8% |
| HLN | Haleon plc | $40.5B | 18.64 | 1.84 | 9.9% |
| 0M3Q.L | Zoetis Inc. | $35.4B | |||
| ZTS | Zoetis Inc. | $30.6B | 11.99 | 9.67 | 69.3% |
| HLN.L | Haleon plc | $29.4B | 18.73 | 1.85 | 9.9% |
| 0SAN.L | Sandoz Group AG | $28.3B | 52.81 | 3.84 | 7.0% |
Price
| Price | $4.16 |
| Market Cap | $156M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -376.95% |
| Return on Invested Capital | -1.25% |
| Return on Assets | -16.25% |
| Gross Margin | 29.68% |
| Operating Margin | -2.12% |
| Net Margin | -30.40% |
Related companies: ACB · ACHV · BIOA · CGC · CVRX · IMMP · OMI
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of LFCR: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks